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A B S T R A C T   
Several promising antimalarial drugs are currently being tested in human trials, such as artefenomel, cipargamin, 
ferroquine and ganaplacide. Many of these compounds were identified using high throughput screens against a 
single species of human malaria, Plasmodium falciparum, under the assumption that effectiveness against all 
malaria species will be similar, as has been observed for other antimalarial drugs. However, using our in vitro 
adapted line, we demonstrated recently that P. knowlesi is significantly less susceptible than P. falciparum to some 
new antimalarial drugs (e.g., cipargamin and DSM265), and more susceptible to others (e.g., ganaplacide). There 
is, therefore, an urgent need to determine the susceptibility profile of all human malaria species to the current 
generation of antimalarial compounds. We obtained ex vivo malaria samples from travellers returning to the 
United Kingdom and, using the [3H]hypoxanthine incorporation method, compared susceptibility to select 
established and experimental antimalarial agents among all major human infective Plasmodium species. We 
demonstrate that P. malariae and P. ovale spp. are significantly less susceptible than P. falciparum to cipargamin, 
DSM265 and AN13762, but are more susceptible to ganaplacide. Preliminary ex vivo data from single isolates of 
P. knowlesi and P. vivax demonstrate a similar profile. Our findings highlight the need to ensure cross species 
susceptibility profiles are determined early in the drug development pipeline. Our data can also be used to inform 
further drug development, and illustrate the utility of the P. knowlesi in vitro model as a scalable approach for 
predicting the drug susceptibility of non-falciparum malaria species in general.   
1. Introduction 
Almost all human malaria infections are caused by six Plasmodium 
species: P. falciparum, P. vivax, P. malariae, P. ovale curtisi, P. ovale 
wallikeri, and the zoonotic P. knowlesi (Singh et al., 2004; Sutherland 
et al., 2010). However, with advances in genomics it is becoming 
evident that this number could be increased to include other primate 
malaria species now known to cause some human infections, including 
P. simium (Brasil et al., 2017), P. brasilianum (Lalremruata et al., 2015) 
and P. cynomolgi (Raja et al., 2020; Ta et al., 2014). While P. falciparum 
continues to exert the greatest burden of morbidity and mortality 
world-wide, P. vivax infections make up 75 % of the cases detected in the 
WHO Region of the Americas and 50 % of the cases detected in WHO 
South-East Asia Region (World Health Organization, 2020). In Malaysia, 
both P. falciparum and P. vivax infections have almost been eliminated 
while the zoonotic P. knowlesi infections have increased from 1600 cases 
in 2016 to over 4000 cases in 2018, and despite a small decline in 2019, 
nonetheless resulted in 12 deaths in 2018–19 (World Health Organiza-
tion, 2020). 
Since the turn of the century new drug development has increasingly 
been driven by high-throughput screens of large libraries of compounds 
against whole parasites, and thousands of new active chemical scaffolds 
have been identified (Gamo et al., 2010; Guiguemde et al., 2010; Plouffe 
et al., 2008). However, these screens have only been performed using P. 
falciparum parasites, as this is historically the only human malaria spe-
cies that could be cultured in vitro continuously (Trager and Jensen, 
1976), and in large numbers. However, the recent adaptation of the 
zoonotic parasite P. knowlesi to grow continuously in human red blood 
cells (Gruring et al., 2014; Lim et al., 2013; Moon et al., 2013) has 
enabled detailed exploration of in vitro drug susceptibility in a 
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non-falciparum parasite species. Furthermore, both species can be 
cultivated in vitro under identical conditions allowing for a direct com-
parison of drug susceptibility (van Schalkwyk et al., 2017). Using the P. 
knowlesi in vitro model we have shown recently that some existing and 
experimental antimalarial agents exhibit large and significant species 
differences in susceptibility (van Schalkwyk et al., 2017, 2019). It re-
mains an open question as to whether the other human-infecting malaria 
species (e.g., P. vivax, P. malariae or P. ovale spp.) are more like P. fal-
ciparum or P. knowlesi in their drug susceptibility profiles. In the absence 
of in vitro continuous cultivation methods for these other human malaria 
species, it is necessary to use ex vivo drug assays to obtain drug sus-
ceptibility data. 
For this study, we developed the following two hypotheses: (a) that 
there are significant species differences in drug susceptibility, particu-
larly to some of the newer antimalarials under development, and (b) that 
the drug susceptibility profiles of P. vivax, P. malariae and P. ovale spp. 
will be more similar to P. knowlesi than to P. falciparum, given their 
phylogenetic relatedness (Rutledge et al., 2017). In order to test these 
hypotheses we obtained infected whole blood samples representing the 
six common human-infecting malaria species from the Public Health 
England Malaria Reference Laboratory (MRL), United Kingdom. We 
then performed ex vivo drug susceptibility testing on short term cultures 
to compare the activity of a select panel of established and experimental 
antimalarial agents. 
2. Materials and methods 
2.1. Compounds 
Established antimalarial drugs and investigational compounds were 
supplied by the Medicines for Malaria Venture, Geneva, Switzerland. 
Chloroquine stocks were prepared in sterile distilled water and all other 
compounds were dissolved in DMSO. [3H]hypoxanthine monohydro-
chloride [1 mCi (37 MBq)] was purchased from PerkinElmer (Catalogue 
number: NET177001MC). 
2.2. ex vivo parasite sample acquisition 
Whole blood samples from all malaria species were obtained from 
the Malaria Reference Laboratory (MRL) at the London School of Hy-
giene & Tropical Medicine. All patient identifiers were removed and a 
code assigned to each sample. Samples received were typically between 
500 μL and 2500 μL and species were confirmed by microscopy before 
use. Only mono-infections (i.e., no mixed species infections) were used 
in this study. Approval for the study was obtained by the Research Ethics 
Committee of the London School of Hygiene & Tropical Medicine 
(Application reference: 14710) and the National Health Service (NHS), 
London-Chelsea Research Ethics Committee (Application reference: 18/ 
LO/0738). 
2.3. In vitro parasite cultivation 
P. knowlesi (clone A1-H.1) and P. falciparum (clone 3D7) were 
maintained in culture as described previously (van Schalkwyk et al., 
2019). 
2.4. Sample preparation 
Whole blood (ex vivo) samples were first transferred into micro-
centrifuge tubes. The samples were then centrifuged at 7000×g for 2 min 
after which the plasma and buffy coat was removed by aspiration. The 
infected erythrocytes were then washed twice with RPMI 1640 (Sigma 
product R5886). Parasites received, particularly non-falciparum species, 
are often present at low parasitaemia (<1 %). Therefore, for the drug 
susceptibility assays, parasite stocks were prepared at 2 % haematocrit 
without diluting the parasitaemia. 
Comparison assays were set up with the in vitro P. knowlesi (clone A1- 
H.1) and P. falciparum (clone 3D7) lines. These drug susceptibility assays 
were initiated using stocks of unsynchronised parasites with the para-
sitaemia set to 0.1 % and haematocrit set to 2 %. 
2.5. Drug susceptibility assays 
All drug susceptibility assays (ex vivo and in vitro parasites samples) 
were set up in media composed of RPMI 1640 supplemented with 25 mM 
Na2HCO3, 25 mM HEPES, 10 mM D-glucose, 2 mM L-glutamine, 25 mg/ 
mL gentamicin sulphate and 5 g/L AlbuMAX II. 
Drug susceptibility assays were set up in 96-well, flat-bottom 
microplates in a final volume of 200 μL, as described previously (van 
Schalkwyk et al., 2017). Typically, five drugs were screened in duplicate 
per plate. Tritiated hypoxanthine ([3H]hypoxanthine (0.25 μCi/well; 
110 nM)) was added to each well at the beginning of the experiment. 
The parasites were exposed to the drugs for one complete life cycle: 
24 h for P. knowlesi (ex vivo), 27 h for P. knowlesi (in vitro), 48 h for P. 
vivax, P. falciparum, P. ovale spp., and 72 h for P. malariae. The plates 
were incubated at 37 ◦C in a modular incubation chamber (Billups- 
Rothenburg Inc.) under a gas mixture of 96 % N2, 3 % CO2 and 1 % O2. 
Upon termination of the assay, the plates were stored at − 80 ◦C 
overnight. 
On the following day the 96-well plates were thawed at 37 ◦C for 1 h, 
and the contents harvested onto a glass fibre printed Filtermat A (Per-
kinElmer product 1450-421), using a 96-well cell harvester (Tomtec, 
Hamden, Conn.). Once dried, the filter is placed on a heating plate. A 
solid scintillator (Meltilex A, PerkinElmer product 1450-441) is placed 
over the filter and heated to 90 ◦C. Once the scintillator has melted into 
the filter, it is removed from the heating plate and allowed to cool and 
set at room temperature. The filter mat is then placed into a sample bag 
(PerkinElmer product 1450-432) and sealed. A Wallac Trilux 1450 
Microbeta scintillation β-counter (PerkinElmer) is used to read the 
amount of radioactivity (in counts per minute) from the [3H]hypoxan-
thine incorporated into parasite material trapped in the filter mats. 
2.6. Parasite DNA isolation 
Genomic DNA was extracted from 200 μL of whole blood from the 
EDTA specimen tube using the QIAamp DNA Blood Mini Kit (Qiagen, 
UK) as per the manufacturer’s instructions. The DNA was stored at 
− 80 ◦C. 
2.7. pfcrt genotyping 
The Plasmodium falciparum chloroquine resistance transporter (pfcrt) 
genotype was determined by multiplex real-time PCR. A small segment 
around codons 72–76 was amplified using a Rotorgene Q thermocycler 
(QIAGEN, Germany) in the presence of three dual-labelled probes 
complementary to CVMNK (FAM fluorophore), CVIET (JOE fluo-
rophore) and SVMNT (ROX fluorophore), as described previously 
(Sutherland et al., 2007; van Schalkwyk et al., 2013). For data analysis, a 
threshold for each probe was set manually using positive and negative 
controls. 
2.8. Plasmodium ovale species discrimination 
Discrimination between Plasmodium ovale curtisi and Plasmodium 
ovale wallikeri was achieved by quantitative real-time PCR (qPCR) of the 
porbp2 locus, as described previously (Oguike et al., 2011). 
2.9. Statistics 
P values for comparisons between EC50 values were calculated using 
Student’s two-tailed t-test for unpaired samples. 
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3. Results 
3.1. Sample acquisition 
We obtained 43 non-falciparum whole blood samples from the Ma-
laria Reference Laboratory for our drug screens over the period from 
June 2018 to December 2019. Most of the samples were Plasmodium 
ovale spp. (21), followed by P. vivax (12) and P. malariae (9) (Supple-
mentary Table 1). Only a single P. knowlesi sample was received for 
testing. In addition, we included seven P. falciparum samples for com-
parison of ex vivo drug susceptibility among human malaria species. Of 
the fifty whole blood samples received in total, not all harboured viable 
parasites that could be successfully assayed for drug susceptibility. P. 
falciparum and P. malariae samples were most likely to yield viable 
parasites for successful drug assays with 86 % (6/7 samples) and 78 % 
(7/9 samples), respectively (Supplementary Table 1). About a third of P. 
ovale assays (8/21 samples; 38 %) produced viable parasites for drug 
screening. P. vivax was the species least likely to yield viable parasites 
for drug assays with only a single sample producing data out of twelve 
received. The single P. knowlesi sample we received was viable. With the 
exception of the P. knowlesi (Malaysia) and P. vivax (Afghanistan) sam-
ple, all other samples were from patients that reported travel to coun-
tries in Africa (Supplementary Table 1). 
3.2. Testing in vitro parasite lines under ex vivo assay conditions 
Before screening the ex vivo samples, we tested the viability of using 
the [3H]hypoxanthine method on our in vitro P. knowlesi (A1-H.1) and P. 
falciparum (3D7) clones. In order to mimic the likely conditions for the 
ex vivo samples, asynchronous in vitro parasite lines were diluted to a low 
starting parasitaemia (0.1 %). After adding the parasites to the drug 
dilutions in the 96-well plate, the [3H]hypoxanthine was added at the 
start of the experiment and drug + hypoxanthine exposure continued for 
a complete life cycle duration (27 h for P. knowlesi and 48 h for P. fal-
ciparum). The [3H]hypoxanthine assay provided a sufficient signal to 
allow for growth inhibition to be measured in spite of the low starting 
parasitaemia of 0.1 %. 
Table 1 reports the results of the drug susceptibility tests. By using 
asynchronous parasite populations, and considering also the different 
life cycle lengths of P. knowlesi versus P. falciparum, we expect natural 
variability in our EC50 determinations. Consequently, we regard only 
differences in EC50 values greater than 3-fold between species as 
potentially important. In Table 1 we show that chloroquine, pyronar-
idine and artefenomel are uniformly potent (EC50 values < 8.8 nM) and 
exhibit a less than 3-fold difference between species. For the other 
compounds there was a greater than 4-fold difference in EC50 values 
between species, with an almost 55-fold difference between species for 
compound AN13762. AN13762 was also the least potent of the drugs 
screened (Table 1). Ganaplacide and dihydroartemisinin provide two 
examples where P. knowlesi is more susceptible than P. falciparum. On 
the contrary, we demonstrate that P. knowlesi is less susceptible to 
cipargamin, DSM265 and AN13762 than P. falciparum (Table 1). For 
comparison, we performed the same drug screens on synchronised ring 
stage cultures of both species (Supplementary Table 2), which are ex-
pected to mimic P. falciparum ex vivo conditions. The EC50 data for 
synchronised ring cultures (Supplementary Table 2) were very similar to 
those of asynchronous parasite cultures presented in Table 1. 
Apart from dihydroartemisinin, these differences between species 
are very similar to those we reported previously using different 
metholodogy for measuring drug susceptibility (SYBR green I readout 
previously (van Schalkwyk et al., 2019; van Schalkwyk et al., 2017) 
versus [3H]hypoxanthine used here, and 1 % starting parasitaemia 
versus 0.1 % used here). Some EC50 values reported in Table 1 are lower 
than those we reported previously (e.g., chloroquine, pyronaridine, 
DSM265) (van Schalkwyk et al., 2017). This is likely due the lower 
starting parasitaemia (inoculum effect) and/or to the absence of 10 % 
serum in the growth media (serum binding) used in this study. Apart 
from pyronaridine (p = 0.8369), all the EC50 differences between species 
were significantly different (p < 0.0080). These data confirm our pre-
vious findings that P. knowlesi is less susceptible than P. falciparum to 
DSM265, cipargamin and AN13762, but is more susceptible to gana-
placide and dihydroartemisinin (van Schalkwyk et al., 2017, 2019). 
3.3. ex vivo species differences 
In Fig. 1 we provide a graphic demonstration of the drug suscepti-
bility data from the viable ex vivo samples received in the course of our 
study. For each drug, a single point in the graph represents the EC50 
value averaged from a distinct, individual ex vivo sample assayed in 
duplicate. Not all drugs could be tested on all ex vivo parasites because of 
the small and variable volumes of sample received within the study. Also 
shown in Fig. 1 are the median EC50 values, which are then reported in 
Table 2 for a more detailed comparison. Statistical analyses were limited 
to comparisons with P. falciparum, P. malariae and P. ovale species and 
were not possible for P. knowlesi and P. vivax as only one sample was 
available for analysis in each case. 
The results in Fig. 1 and Table 2 are summarised through the 
following key findings: 
For chloroquine, across all species, most of the EC50 values are below 
35 nM indicating that most ex vivo parasites remain susceptible to this 
antimalarial drug (Fig. 1). The one exception is a P. falciparum sample 
with a EC50 value of 85 nM. We suspected this parasite sample would 
harbour chloroquine-resistant parasites. Genotyping of archived DNA 
extracted from this sample confirmed the presence of only the 
chloroquine-resistant CVIET genotype, for amino acids 72–76 of PfCRT. 
For dihydroartemisinin, pyronaridine and artefenomel, most EC50 
values were below 10 nM and showed little or no significant difference 
when comparing P. falciparum to P. malariae or P. falciparum to P. ovale 
(Table 2; p ≥ 0.0332). 
Cipargamin, DSM265 and AN13762 were more potent (≥5.66 fold) 
against P. falciparum than all the other species tested. For these com-
pounds, the difference in susceptibility between P. falciparum and 
P. malariae, or P. falciparum and P. ovale, were all significant (Table 2; p 
≤ 0.0126). 
Ganaplacide was the only new antimalarial compound with greater 
potency against non-falciparum species. P. malariae and P. ovale (median 
EC50 values < 5 nM; Table 2) were significantly more susceptible to 
ganaplacide that P. falciparum (median EC50 value = 15.76 nM; P <
Table 1 
Comparison of the susceptibility of the in vitro culture adapted P. knowlesi (A1- 
H.1 clone) and P. falciparum (3D7 clone) under ex vivo conditions. Asynchron-
ized parasites set to a low starting parasitaemia of 0.1 % were exposed to drug 
dilutions for a complete life cycle, and [3H]hypoxanthine was added at the 
beginning of the experiment (see methods section for more details).  
Compound 
Screened 












48 h exposure 
Chloroquine 8.83 ± 0.65 5.38 ± 0.42 1.64 0.0046 
Dihydroartemisinin 0.48 ± 0.04 2.00 ± 0.39 0.24 0.0080 
Pyronaridine 0.38 ± 0.03 0.40 ± 0.08 0.95 0.8369 
Artefenomel 1.05 ± 0.10 2.70 ± 0.34 0.39 0.0014 
Cipargamin 5.20 ± 0.66 1.03 ± 0.15 5.05 0.0003 
Ganaplacide 2.98 ± 0.42 12.3 ± 1.72 0.24 0.0004 
DSM265 44.9 ± 9.49 5.93 ± 0.78 7.57 0.0064 
AN13762 3763 ± 798 69.1 ± 3.65 54.46 0.0006  
a EC50 values report the mean ± SEM from at least 4 experiments, and some up 
to six repeats, each performed in duplicate. 
b p values are calculated by comparing EC50 values for P. falciparum versus P. 
knowlesi using Student’s two-tailed unpaired t-test. 
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We have reported previously on species differences in the suscepti-
bility of Plasmodium falciparum and Plasmodium knowlesi to antimalarial 
drugs, such as cipargamin, DSM265, ganaplacide and proguanil (van 
Schalkwyk et al., 2017, 2019, 2020). These data have been generated 
using in vitro culture-adapted lines. Whether these susceptibility differ-
ences exist in the other species, and whether these different suscepti-
bilities are more comparable to the P. knowlesi phenotype or P. 
falciparum phenotype, is challenging to assess in the absence of routine 
in vitro culture systems for these other species. One way of assessing the 
in vitro drug susceptibility of parasite species lacking representative 
culture-adapted lines is through using an ex vivo platform, where 
infected erythrocytes are removed from the patient and exposed to serial 
dilutions of drugs in a 96-well plate. These parasites are then allowed to 
grow for a period of time (up to one complete life cycle usually, as they 
do not re-invade if not culture-adapted) and the survivors can be 
quantified using either microscopy or measuring [3H]hypoxanthine 
incorporation (Chaorattanakawee et al., 2017; Fatih et al., 2013; 
Kaewpongsri et al., 2011; Mbaye et al., 2017; Rangel et al., 2018). 
Obtaining ex vivo non-falciparum parasites is a challenge, especially in a 
non-endemic setting such as the UK. Some of these challenges include: 
obtaining large numbers of samples, getting hold of viable parasites for 
drug assays in a timely manner, and obtaining mono-infections (as 
mixed infections are often present). We made use of the Malaria Refer-
ence Laboratory (MRL) as our source of ex vivo parasites. 
The MRL is an essential resource of reference-level expertise for the 
surveillance of malaria infections within the United Kingdom, providing 
also diagnostic and advisory services. Suspected or confirmed malaria 
specimens are sent to the MRL by post or courier. Two thick and two thin 
films are requested from each sending laboratory together with a rec-
ommended minimum of 3.0 mL of EDTA-treated blood. The MRL con-
firms the diagnosis of malaria infection by microscopy and extracts DNA 
from the blood sample for additional PCR confirmation. Some blood is 
also archived in case further analyses are required. Despite the length of 
time over which the study was run, only a small number of viable 
samples were obtained for our drug screens (Supplementary Table 1). 
Among the reasons for the limited number of samples of non-falciparum 
species were: (a) blood sample volume received was too small to provide 
excess for our drug screening above that required for characterization 
and archiving by the MRL, (b) the sample received through the post was 
too old to yield viable parasites, (c) samples contained mixed species 
infections, and (d) parasitaemia was too low to generate a signal with 
the [3H]hypoxanthine method. 
We employed the tritiated hypoxanthine ([3H]hypoxanthine) 
method (Desjardins et al., 1979) to measure drug susceptibility of our ex 
vivo samples. Live parasites take up [3H]hypoxanthine and incorporate it 
Fig. 1. Susceptibility of human malaria species, obtained ex vivo through the 
Malaria Reference Laboratory (UK), to established and experimental antima-
larial drugs. Each data point for a particular drug shows the average EC50 value 
from duplicate assays on a single, distinct ex vivo sample (i.e., no repeats). 
Median EC50 values and the 95 % confidence value are shown for P. falciparum, 
P. malariae and P. ovale species. For P. knowlesi and P. vivax only one ex vivo 
sample was successfully screened for EC50 data. Not all drugs could be tested 
against all ex vivo parasites because of small and variable volumes of sample 
received within the study. 
Table 2 
Comparison of the susceptibility of the ex vivo Plasmodium species. Parasites were exposed to serial drug dilutions for a complete life cycle, and [3H]hypoxanthine was 
added at the beginning of the experiment (see methods section for more details).  
Compound screened Median EC50 values (nM)a (range) Fold Difference (p-value) 
P. falciparum P. malariae P. ovale spp. P. knowlesi P. vivax Pm/Pf Po/Pf Pk/Pfb Pv/Pfb 
Chloroquine 22.61 (3.85–85.0) 16.38 (9.77–34.4) 5.69 (4.16–24.3) 6.18 18.46 0.72 (0.4247) 0.25 (0.1130) 0.27 0.82 
Dihydroartemisinin 1.30 (0.94–2.57) 5.45 (2.27–20.0) 1.23 (0.77–5.92) 1.64 0.42 4.19 (0.0420) 0.95 (0.5639) 1.26 0.32 
Pyronaridine 0.57 (0.11–1.49) 2.57 (0.88–4.41) 1.63 (0.39–7.47) 1.86 ND 4.51 (0.0332) 2.86 (0.1223) 3.26 ND 
Artefenomel 0.76 (0.26–1.63) 1.72 (0.55–2.89) 0.78 (0.76–0.80) 3.43 ND 2.26 (0.4715) 1.03 (0.8504) 4.51 ND 
Cipargamin 1.21 (1.02–1.79) 6.85 (4.92–8.68) 8.06 (4.90–17.85) 9.46 ND 5.66 (<0.0001) 6.66 (0.0038) 7.82 ND 
Ganaplacide 15.76 (7.65–18.69) 3.40 (1.18–5.76) 4.72 (1.30–9.60) 4.57 ND 0.22 (0.0066) 0.30 (0.0236) 0.29 ND 
DSM265 2.51 (0.23–12.18) 450 (268–511) 463 (207–769) 76.4 28.2 179.3 (0.0064) 184.5 (0.0105) 30.44 11.24 
AN13762 226 (45.2–354) 4166 (2022–8317) 1708 (776–1789) 3644 2664 18.43 (0.0126) 7.56 (0.0023) 16.12 11.79 
ND = Not done. No P. vivax EC50 data are available for these compounds. 
a Each EC50 value is determined from the average of a duplicate experiment performed on a single ex vivo sample. 
b No p-value could be calculated as only a single EC50 value was obtained. 
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into their nucleic acids. Thus, using the [3H]hypoxanthine method to 
measure ex vivo growth eliminates the need to subjectively assess 
schizont maturation which is the method more widely used in other ex 
vivo studies in endemic countries (Chaorattanakawee et al., 2017; Rus-
sell et al., 2003, 2012). Using our approach, the [3H]hypoxanthine was 
added at the beginning of each experiment, and surviving parasites 
allowed to incorporate the DNA precursor for the entire length of the 
drug exposure, an approach previously adopted by Arnold et al. for 
testing P. knowlesi in vitro (Arnold et al., 2016). In our assays no unla-
belled hypoxanthine was added so that parasites were forced to incor-
porate only the [3H]hypoxanthine, thereby ensuring the signal 
generated was as large as possible even with low parasitaemia samples. 
Traditionally, in vitro drug assays are initiated with parasites growing in 
a small amount of unlabelled hypoxanthine (i.e., 2 μM), with the triti-
ated hypoxanthine added 24 h before the end of the experiment to allow 
for the radiolabel to be incorporated into DNA. Furthermore, most ex 
vivo drug assays on P. vivax use large amounts of human serum (20 %) in 
their growth media. Human serum contains hypoxanthine which may 
also compete for uptake into DNA by parasites (Psychogios et al., 2011). 
We observed that both unlabelled hypoxanthine and high serum media 
reduced the incorporation of [3H]hypoxanthine, thereby reducing the 
signal window and the Zˊ value (a measure of the robustness of the 
assay) (Supplementary Figure 1). Since the in vitro parasites were able to 
grow successfully in the presence of only radiolabeled hypoxanthine, 
our ex vivo experiments were run without unlabelled hypoxanthine and 
high serum. Serum has previously been shown to be important in sup-
porting P. vivax ex vivo growth (Brockelman et al., 1985; Chotivanich 
et al., 2001), and thus its absence here may have contributed to the low 
success rate of our P. vivax and P. ovale assays. However, the conditions 
adopted were able to support growth of the in vitro lines as well as the ex 
vivo P. knowlesi sample, most P. malariae and P. falciparum samples, and 
several P. ovale samples. Future work could focus on identifying optimal 
conditions for assaying P. vivax and P. ovale species ex vivo in 
non-endemic settings that allow for improved [3H]hypoxanthine 
incorporation so as to maintain a good signal window and assay quality. 
Another reason for the small number of viable P. vivax and P. ovale 
samples could be the use of anticoagulant used during blood collection. 
Samples to the MRL were all received from hospitals using the recom-
mended purple-top Vacutainer® tubes containing EDTA (1.8 mg/mL) as 
anticoagulant. EDTA is reported to have a toxic effect on parasite 
viability (Russell et al., 2012). This study used passive sample collection 
so we were unable to alter the method for blood collection. Interestingly, 
we have collected several ex vivo P. falciparum samples by similar 
methodology since 2012 and showed a high (>90 %) success rate for 
culture adaptation (e.g. (van Schalkwyk et al., 2013)). Also, most 
P. falciparum and P. malariae samples, and the single P. knowlesi sample 
used in this study were successfully assayed. This suggests that, if inhi-
bition of growth by EDTA is a factor, some species (e.g., P. vivax) may be 
more susceptible to this toxicity than others. 
Despite these limitations, we were able to obtain a small number of P. 
malariae, P. ovale and P. falciparum parasites to assay successfully for 
drug susceptibility. We limited our drug screen to only seven P. falcip-
arum samples as these would provide a similar number of comparator 
samples to the P. malariae and P. ovale spp. 
In the course of the study we obtained only one P. knowlesi sample – 
this species is rarely detected among malaria cases in the UK - but the 
sample volume and excellent viability allowed us to screen all our drugs 
of interest. The P. knowlesi ex vivo EC50 data (Table 2) showed remark-
able congruence with the EC50 data reported in Table 1 for the in vitro 
A1-H.1 clone, tested under similar ex vivo conditions. For P. falciparum, 
there was also good agreement between ex vivo and in vitro data 
observed for most drugs. This provides us with confidence in the 
methodology used to screen the other species for drug susceptibility. 
The ex vivo drug susceptibility data reported here for P. malariae and 
P. ovale spp., and compared with P. falciparum, confirm our hypotheses 
that there are species differences in drug susceptibility, and that these 
susceptibility profiles are more similar to the zoonotic P. knowlesi than to 
P. falciparum (Table 2). With a few exceptions, there were generally 
small differences in median EC50 values for chloroquine, pyronaridine, 
dihydroartemisinin and artefenomel for P. malariae or P. ovale when 
compared with P. falciparum (Table 2). Most comparisons between 
species for these compounds were not significantly different or were 
only marginally so (Table 2). 
For the new antimalarial agents cipargamin, DSM265 and AN13762, 
the differences in median EC50 values between P. malariae or P. ovale 
spp. compared with P. falciparum were large (>5.6 fold; and up to 184- 
fold for DSM265) and were, in many cases, highly significant (Table 2). 
The reduced susceptibility of P. malariae or P. ovale spp. compared with 
P. falciparum to these three antimalarial agents match the susceptibility 
profiles obtained in comparisons of P. knowlesi with P. falciparum either 
in vitro (Table 1) or ex vivo (Table 2). Our ex vivo cipargamin suscepti-
bility data are similar to those reported previously for ten P. falciparum 
and ten P. vivax isolates from Thailand (median EC50 values < 10 nM). 
However, there was no species difference in drug susceptibility reported 
between P. vivax and P. falciparum in that study (Rottmann et al., 2010). 
Of note, different methodologies were employed in those ex vivo drug 
screens. Cipargamin activity against either rings stages or trophozoite 
stages was determined using a modified WHO schizont maturation assay 
and the growth media used was McCoy’s 5A medium supplemented with 
20 % AB+ human serum as compared to our RPMI-based media lacking 
serum (Russell et al., 2003; Sharrock et al., 2008). Nevertheless, without 
more P. vivax data in our study, it is impossible to draw further con-
clusions about potential species differences with P. falciparum for com-
parison to that study. For DSM265, ex vivo drug assays performed by 
others revealed a 5-fold lower susceptibility to P. vivax versus P. falcip-
arum in isolates sampled from Papua, Indonesia (Phillips et al., 2016). 
Coupled with our ex vivo data reported here, this confirms that DSM265 
is more potent against P. falciparum than against any of the other malaria 
species. 
Conversely, P. malariae and P. ovale spp. are more susceptible to 
ganaplacide than P. falciparum. Again, this greater susceptibility to 
ganaplacide is more similar to the profile of P. knowlesi than to that of P. 
falciparum (Tables 1 and 2). Our data are in close agreement with a 
recent study comparing the ex vivo activity of ganaplacide (KAF156) 
against P. falciparum and P. vivax. Using parasites obtained from 
Thailand and Indonesia, P. falciparum samples were shown to be less 
susceptible to ganaplacide (median EC50 value = 12.6 nM) than P. vivax 
samples (median EC50 value = 5.5 nM) (Kuhen et al., 2014). 
We were only able to obtain data from a single P. vivax ex vivo 
sample, and could only screen four drugs with the limited sample size 
(Table 2). The reason for this high attrition rate for this species (only 1/ 
12 successful assays, Supplementary Table 1) compared with other 
species tested, is unclear. As mentioned above, it could be related to the 
absence of serum in our assays or the use of EDTA vials for blood 
collection. However, the P. vivax drug susceptibility data we obtained 
are similar to the data reported for the other non-falciparum malaria 
species. The EC50 data for chloroquine and dihydroartemisinin against 
our non-falciparum species were less than 4-fold different from the 
median P. falciparum EC50 values. However, DSM265 and AN13762 
were 11-fold less potent against P. vivax than P. falciparum, confirming 
trends observed for the other non-falciparum species. 
It is interesting to note how similar the species differences were for 
the non-falciparum species compared to P. falciparum for cipargamin 
(5.66–7.82 fold), ganaplacide (0.22–0.30 fold) and AN13762 
(7.56–18.43 fold; Table 2). However, there were large differences 
observed for DSM265, ranging from around 11-fold for P. vivax to 184- 
fold for P. ovale spp. when compared to P. falciparum (Table 2). Further 
studies are needed to confirm these data on more P. vivax and P. knowlesi 
samples, and to investigate this remarkable diversity in susceptibility to 
DSM265, an inhibitor of the enzyme dihydroorotate dehydrogenase 
(DHODH) (Phillips et al., 2015). 
It should be noted that cipargamin remains highly potent against all 
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species in spite of the lower susceptibility of non-falciparum species 
reported here (Table 2). Also, ganaplacide is revealed to be more potent 
against non-falciparum species which is good news. However, the ob-
servations of significantly lower potency of DSM265 and AN13762 
against non-falciparum species are potentially of critical importance to 
future drug development (Table 2). We cannot directly predict the 
clinical relevance of our in vitro findings in the absence of in vivo data 
from non-falciparum malaria patients, but it would be remarkable if the 
large species-specific differences observed here were not reflected in 
different clinical outcomes in treated infections. For example, a recent 
clinical trial in Peru showed that DSM265 was highly effective at 
clearing most P. falciparum infections while none of the P. vivax in-
fections were cleared, even at higher doses than the ones used to treat P. 
falciparum infections (Llanos-Cuentas et al., 2018). Therefore, based on 
our ex vivo drug susceptibility data presented here, we might predict that 
DSM265 treatment would also be insufficient to clear either P. malariae 
and P. ovale spp. infections, given that these species are less susceptible 
to DSM265 than P. vivax. 
5. Conclusion 
In this study we sought to test two hypotheses: (a) that there are 
species differences in drug susceptibility, and (b) that the other non- 
falciparum malaria species (P. vivax, P. malariae and the P. ovale spe-
cies) will be more similar to P. knowlesi in their drug susceptibility 
profiles than to P. falciparum. Using a small panel of ex vivo P. malariae, 
P. ovale, and P. falciparum samples, and single P. vivax and P. knowlesi 
samples, we demonstrate that there are indeed species differences in 
drug susceptibility, particularly to the experimental antimalarial agents 
cipargamin, ganaplacide, DSM265 and AN13762. Furthermore, the 
susceptibility profiles of P. malariae and P. ovale spp. are more similar to 
the susceptibility profile of P. knowlesi (in vitro and ex vivo) than of P. 
falciparum. This reinforces the value of complementing in vitro drug 
discovery approaches using P. falciparum with concurrent screening 
against P. knowlesi. 
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